Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

36P - Eligibility and outcomes in phase I clinical trials testing targeted therapy, immunotherapy and combinations: A single-institution study

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Antonio Marra

Citation

Annals of Oncology (2020) 31 (suppl_1): S17-S18. 10.1016/annonc/annonc81

Authors

A. Marra, S. Morganti, G. Viale, P. Tarantino, D. Trapani, E. Ferraro, P. Zagami, M. Repetto, E. Nicolò, P. D'Amico, P. Trillo Aliaga, M.A. Massaro, C. Busacca, I. Minchella, C. Belli, M. Locatelli, L. Mazzarella, A. Esposito, C. Criscitiello, G. Curigliano

Author affiliations

  • Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia IRCCS, University of Milan, 20141 - Milan/IT
More

Resources

Abstract 36P

Phase I clinical trials are an essential step for the development of new anticancer treatments. Next-generation phase I trials investigating novel drugs led to consistent improvements in terms of response rates and survival of the enrolled pts. The aim of our study is to evaluate the outcomes of patients enrolled in phase I trials testing targeted therapies (TT), immunotherapy (IT), and combinations.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings